


Exhibit 12

**Redacted Version of Document
Proposed to be Filed Under Seal**

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
SOUTHERN DIVISION

CHROMADEx, INC.,)	
)	
Plaintiff,)	
)	
)	
vs.)	Case No. SACV 16-02277-CJC
)	
ELYSIUM HEALTH, INC.,)	
)	
Defendant.)	
)	
<hr/> ELYSIUM HEALTH, INC.,)	
)	
Counterclaimant,)	
)	
vs.)	
)	
CHROMADEx, INC.,)	
)	
Counter-Defendant.)	
<hr/>)	

DEPOSITION OF



NOVEMBER 29, 2018

Reported by:
VICTORIA RUSSO, CRR
JOB NO. 18-72097

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
SOUTHERN DIVISION

CHROMADEX, INC.,)
)
 Plaintiff,)
)
) Case No.SACV 16-02277-CJC
)
 vs.)
)
 ELYSIUM HEALTH, INC.,)
)
 Defendant.)
)
 _____)
 ELYSIUM HEALTH, INC.,)
)
 Counterclaimant,)
)
 vs.)
)
 CHROMADEX, INC.,)
)
 Counter-Defendant.)
 _____)

VIDEOTAPED DEPOSITION of [REDACTED], PH.D.,
 taken on behalf of the Plaintiff, at [REDACTED],
 [REDACTED] at
 8:38 a.m., on Thursday, November 29, 2018, before
 Victoria Russo.

1 identify whether these specifications were accurate?

2 A. What do you mean "accurate"?

3 Q. Did you ever perform any tests on these
4 specifications?

5 A. I don't understand the question.
6 Basically when we develop our own product, then we
7 test our samples, how does it look.

8 Q. When you receive these --

9 A. You don't perform tests on the
10 specifications. You perform tests on the sample.

11 Q. When you received these specifications,
12 what did you do with them?

13 A. Nothing.

14 Q. Would you turn to the document right
15 after that attachment, document 53730 at the bottom.
16 Look at the top of that. It's HPLC method for
17 nicotinamide riboside chloride; does that look right
18 to you?

19 A. That's correct.

20 Q. Is this the same HPLC we were talking
21 about earlier?

22 A. Yes.

23 Q. And what is this document?

24 A. This is the method for analysis of the
25 product.

1 Q. Do you remember seeing this at the
2 beginning of the development process?

3 A. Well, I don't remember but I'm pretty
4 sure Ed must have given it to us, yes.

5 Q. Did [REDACTED] ever develop an HPLC method for
6 NR?

7 A. Yes.

8 Q. Do you remember using this document in
9 that process?

10 A. I think, typically, when we get
11 something, we use it when we start development work
12 but as we go along, then we modify to make it much
13 better for our needs.

14 Q. So did you assess the effectiveness of
15 this method?

16 A. That is, typically, done by the method
17 development group.

18 Q. Do you remember how that assessment
19 turned out in this case?

20 A. Well, from what I -- from one of my
21 like discussions with the method development group, I
22 think they ended up spending a lot of time to modify
23 the method or come up with their own method.

24 Q. Do you remember when that HPLC method
25 at [REDACTED] was completed?

1 A. The development?

2 Q. Right.

3 A. I think probably before we went to
4 manufacturing. So I think from -- I think from
5 development we started some time in 2016 and went to
6 manufacturing in 2017. So it was about six to eight
7 months or about a year before.

8 Q. Did [REDACTED] complete the HPLC method before
9 commercialization of the product?

10 A. That's correct.

11 Q. And when I say "commercialization",
12 what do you understand me to mean?

13 A. When we go to the plant for making the
14 batches.

15 Q. Before the plant, the [REDACTED] plant started
16 to produce commercial batches, the HPLC method had
17 been finalized?

18 A. That's correct.

19 Q. When I say "commercial batches", what
20 do you understand that to mean?

21 A. Anything made in the plant.

22 Q. What would you call batches that were
23 made at other facilities than the plant?

24 A. The only other facility are R&D
25 facility.

1 I, VICTORIA RUSSO, a Certified Shorthand
2 Reporter of the State of California, do hereby certify:

3 That the foregoing proceedings were taken
4 before me at the time and place herein set forth; that
5 any witnesses in the foregoing proceedings, prior to
6 testifying, were administered an oath; that a record
7 of the proceedings was made by me using machine
8 shorthand which was thereafter transcribed under my
9 direction; that the foregoing transcript is a true
10 record of the testimony given.

11 Further, that if the foregoing pertains to
12 the original transcript of a deposition in a Federal
13 Case, before completion of the proceedings, review of
14 the transcript [] was [x] was not requested.

15 I further certify I am neither financially
16 interested in the action nor a relative or employee of
17 any attorney or any party to this action.

18 IN WITNESS WHEREOF, I have this date
19 subscribed my name.

20
21 Dated: December 12, 2018



VICTORIA RUSSO, CRR

22
23
24
25